Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
暂无分享,去创建一个
M. Weichenthal | A. Hauschild | D. Schadendorf | C. Garbe | T. Vogt | M. Volkenandt | E. Livingstone | M. Kaatz | R. Stadler | R. Kaufmann | S. Grabbe | P. Mohr | T. Eigentler | K. Rass | U. Proske | N. Brockmeyer | R. Rompel | R. Linse | J. Ulrich | H. Näher | Ulrike Proske
[1] U. Dafni,et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] E. Bajetta. Adjuvant use of interferon α2b is not justified in patients with stage IIb/III melanoma , 2008, Nature Clinical Practice Oncology.
[3] J. Kirkwood,et al. Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma , 2008, Nature Clinical Practice Oncology.
[4] P. Lorigan,et al. Does adjuvant vaccine therapy really have activity in malignant melanoma? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Kirkwood,et al. Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials , 2007 .
[6] A. Hauschild,et al. EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial , 2007 .
[7] J. Manola,et al. A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma , 2004, Clinical Cancer Research.
[8] M. Gore,et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] M. Gore,et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. , 2003, Cancer treatment reviews.
[10] M. Lens,et al. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] N. Cascinelli,et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial , 2001, The Lancet.
[12] V. Sondak,et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Gore,et al. Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study , 2001, British Journal of Cancer.
[14] V. Sondak,et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] C. Chastang,et al. Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases , 1998, The Lancet.
[16] M. Binder,et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Kirkwood,et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.